Enveric Biosciences Secures 23rd U.S. Patent for Novel Neuroplastogenic Compounds Targeting Mental Health Disorders
I'm PortAI, I can summarize articles.
Enveric Biosciences has secured its 23rd U.S. patent, U.S. Patent No. 12,428,408, for novel neuroplastogenic compounds aimed at treating mental health disorders. The patent covers a series of fused heterocyclic mescaline derivatives that target serotonin receptors and promote neuroplasticity. This achievement is part of the company's strategy to enhance its intellectual property portfolio and develop next-generation treatments for neuropsychiatric conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments